Inhibition of the serotoninergic uptake system by MK-212 (6-chloro-2-[1-piperazinyl]-pyrazine)

Related Experiment Videos

B V Clineschmidt, J A Totaro, A B Pflueger

Pharmacological Research Communications

|March 1, 1978

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Pharmacology of L-744,453, a novel nonpeptidyl endothelin antagonist.

Life sciences·1996

Conformationally constrained o-tolylpiperazine camphorsulfonamide oxytocin antagonists. Structural modifications that provide high receptor affinity and suggest a bioactive conformation.

Bioorganic & medicinal chemistry·1994

1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor.

Journal of medicinal chemistry·1994

Identification of an orally active, nonpeptidyl oxytocin antagonist.

The Journal of pharmacology and experimental therapeutics·1993

In vitro pharmacology of L-158,809, a new highly potent and selective angiotensin II receptor antagonist.

The Journal of pharmacology and experimental therapeutics·1992

Radioligand binding studies reveal marked species differences in the vasopressin V1 receptor of rat, rhesus and human tissues.

Life sciences·1992

See all related articles